The pharma industry spends more on advertising, lobbying, marketing and PR than they do on R&D. They highlight the high development costs to the govt. and public to justify their obscene pricing. The cost is high; the failure rate of drug trials is very high but pails into insignificance when compared to the revenue streams of the successful products. Humira earns nearly US$20Billion/year by itself. That buys a lot of research.
BOT - Anything but charting, page-207
-
- There are more pages in this discussion • 9,860 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
0.050(14.3%) |
Mkt cap ! $724.0M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 40.0¢ | 35.5¢ | $6.075M | 15.87M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 287187 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 1920397 | 33 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |